Advanced Solid Tumors Harboring MAPK Pathway Alterations
1 clinical trials · Condition
◉ Watch Advanced Solid Tumors Harboring MAPK Pathway Alterations
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations. (NCT05488821) | Qilu Pharmaceutical Co., Ltd. | 2022-06-14 |
Track Advanced Solid Tumors Harboring MAPK Pathway Alterations automatically
Every clearance here is in the API, with alerts when new ones post.